DelveInsight’s “Liver Failure Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Liver Failure, historical and forecasted epidemiology as well as the Liver Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Liver Failure market report provides current treatment practices, emerging drugs, Liver Failure market share of the individual therapies, and current and forecasted Liver Failure market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Liver Failure treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Liver Failure market.
Key Highlights of Liver Failure Market Report
In the study by Stravitz and Lee (2019), data were collected between Jan 1, 1998 and March 31, 2019. PubMed and MEDLINE using the terms “acute liver failure” or “fulminant hepatic failure” were searched, to identify studies and publications not already familiar to the authors, with no restrictions on the date or location of publication.
The total number of patients enrolled was 2614; paracetamol accounted for 46% of cases, 12% of cases had indeterminate causes, and drug-induced liver injury accounted for 11% of cases.
Key Benefits of the Liver Failure Market Report
The report covers a descriptive overview of Liver Failure, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
Comprehensive insight has been provided into the Liver Failure epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Liver Failure is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Liver Failure market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Liver Failure market
Got queries? Click here to know more about the Liver Failure Market Landscape
Liver Failure Overview
Acute liver failure (ALF) is the development of sudden, severe hepatic dysfunction from an acute insult to the liver, associated with the onset of hepatic encephalopathy and coagulation abnormalities. American Association for the study of Liver Diseases (AASLD) defines it as the evidence of coagulation abnormality, usually an international normalized ratio above 1.5, and any degree of mental alteration (encephalopathy) in a patient without preexisting liver disease and with an illness of fewer than 26 weeks’ duration. The condition is categorized into three categories based on the interval between the development of jaundice and the onset of encephalopathy. The first is a hyperacute liver failure in which the onset of encephalopathy is within seven days after the development of jaundice. Second, acute liver failure in which the onset of encephalopathy is within eight to 28 days after the development of jaundice, and the third, sub-acute liver failure in which the onset of Encephalopathy is more than 5 weeks but less than 12 weeks after the development of jaundice. A diverse array of etiologies can cause ALF which includes drugs and toxins like Acetaminophen, and Amanita phalloides; viral infections like Hepatitis A, B, and E; vascular problems like shock, heat stroke, tumor-infiltrating the liver; metabolic etiologies like Wilson’s disease, acute fatty liver of pregnancy, autoimmune hepatitis and others. Also, in many cases, the cause of the acute liver failure remains unknown.
Liver Failure Epidemiological Segmentation
Liver Failure total incident cases
Liver Failure total gender-specific cases
Liver Failure total etiology-specific cases
Liver Failure total age-specific cases
Liver Failure Market Outlook
The Liver Failure market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Liver Failure market trends by analyzing the impact of current Liver Failure therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Liver Failure market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Liver Failure market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Liver Failure market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Liver Failure Market Landscape
Liver Failure Key Companies
Grifols Therapeutics
Merck
Accerta Pharmaceuticals
Acaza Bioscience
Promethera Therapeutics
And many others
Liver Failure Key Therapies
Elbasvir
Ridaforolimus
TAK-242
FYU-981
Prograf
Table of Contents
Key Insights
Report Introduction
Executive Summary of Liver Failure Market
Disease Background and Overview
Epidemiology and patient population
The United States
EU 5
Liver Failure Market Emerging Therapies
Market Access and Reimbursement of Therapies
Appendix
Liver Failure Market Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
Click here to read more about Liver Failure Market Landscape
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
